KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Cash Flow (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Net Cash Flow data on record, last reported at -$7.9 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 24.37% year-over-year to -$7.9 million; the TTM value through Dec 2025 reached $49.6 million, up 4.09%, while the annual FY2025 figure was $49.6 million, 4.09% up from the prior year.
  • Net Cash Flow reached -$7.9 million in Q4 2025 per AQST's latest filing, down from $68.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $71.3 million in Q1 2024 and bottomed at -$13.3 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $4.5 million, with a median of -$3.0 million recorded in 2021.
  • The widest YoY moves for Net Cash Flow: up 18342.46% in 2024, down 582.75% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$3.1 million in 2021, then soared by 374.65% to $8.6 million in 2022, then crashed by 112.12% to -$1.0 million in 2023, then plummeted by 507.37% to -$6.3 million in 2024, then fell by 24.37% to -$7.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$7.9 million in Q4 2025, $68.5 million in Q3 2025, and -$8.1 million in Q2 2025.